“The good fortune of Grifols Clayton’s production over the past 50 years is due to the hard work of thousands of painters who are committed to helping patients lead fuller, fuller lives,” said Thomas Glanzmann, CEO of Grifols. “A component of Grifols, Clayton has been a crown jewel of the company, a driving force for cutting-edge medicines and sustainable production practices that has been a major contributor to our expansion over the past 15 years. “
“Our facility in Clayton represents each and every aspect that makes our company special: reliable medicines, exceptional engineering, sustainable operations, and an engaged workforce that goes above and beyond every day to make a definitive impact on patients,” said Nacho Abia. , Chief Executive Officer of Grifols. “” As we celebrate the golden anniversary of this historic site, we also take a look back at all of its long-term achievements. “
A style of innovation
The site, which operates 24 hours a day, 365 days a year, is an engineering marvel. Its advanced industry-leading robotics cover the entire production cycle of plasma-based medicines, from fractionation to purification, filling and packaging of the definitive medicine. Clayton’s inventions are replicated at Grifols’ new production facilities in Montreal, Canada, and Cairo, Egypt.
Naturally sustainable
On the Clayton campus, Grifols maintains a wildlife habitat domain of three hundred acres (121 hectares) to protect and protect biodiversity. The reserve includes eight walking trails and is home to more than three hundred species of plants and animals. This domain holds a GOLD certification for conservation. certification, the highest point that can be obtained from the Wildlife Habitat Council.
In 2019, Grifols became the first pharmaceutical company in the U. S. to obtain Zero Waste-to-Landfill validation from Underwriters Laboratories thanks to Clayton diverting 99% of its waste from landfills. It has maintained this validation for five consecutive years. years.
The site is also home to the first LEED-rated construction in Johnston County, where the city of Clayton is located. The Grifols campus now has two LEED amenities, as well as two Green Globe buildings qualified through the Green Building Initiative (GBI), a non-profit organization committed to building functionality and reducing climate impacts.
Building on a Legacy of Commitment
Although still committed to the production of plasma-based medicines, the Clayton site has operated under various names in its 50-year history, beginning operations as Cutter Laboratories in 1974 before becoming part of Miles Laboratories in 1983. In 1995, the site began operating under the name of its parent company, Bayer, retaining this logo for a decade until it was purchased by Talecris Biotherapeutics in 2005. Grifols acquired the Clayton facility in 2011 and with a project to improve the health and well-being of others around the world. . , continued the site’s legacy of generating quality products for the benefit of patients. Today, Grifols employs more than 1,600 people at the site, with another 400 at nearby Research Triangle Park, the largest studio park in the United States.
MEDIA CONTACTS:
Grifols Press Room
SpainDuomo ComunicaciónTel. : 34 311 92 89 – 34 311 92 90Raquel Lumbreras (Tel. 34. 659. 572 185)Raquel_lumbreras@duomocomunicacion. com
Borja Gómez (Tel. 34. 659. 572 185)Borja_gomez@duomocomunicacion. com
InvestorsInvestor Relations & durableinversores@grifols. com Development – inversores@grifols. comTel. 34 571 02 21
About Grifols
Patient desires and Grifols’ growing awareness of many chronic, rare, widespread and rarely life-threatening diseases are driving the company’s innovation in plasma and other biopharmaceuticals to improve quality of life. Grifols focuses on the treatment of pathologies in a wide variety of curative areas: immunology, hepatology and critical care, pulmonology, hematology, neurology and infectious diseases.
Grifols, a pioneer in the plasma industry, continues to expand its network of donation centers, the largest in the world with more than 390 in North America, Europe, Africa, the Middle East and China.
As an identified leader in transfusion medicine, Grifols offers a full range of responses designed for safety from donation to transfusion, as well as clinical diagnostic technologies. It manufactures high-quality biological materials for life science research, clinical trials, and pharmaceuticals and diagnostics. manufacturing. The company also provides tools, information, and facilities that enable hospitals, pharmacies, and healthcare professionals to successfully provide specialized medical care.
With more than 23,000 employees in more than 30 countries and regions, Grifols is committed to a sustainable business style that sets the standards for constant innovation, quality, protection and moral leadership.
For more information about Grifols, see grifols. com
LEGAL NOTICE
Facts and figures contained in this report that do not refer to past knowledge are “long-term projections and assumptions. ” Words and expressions such as “believe”, “expect”, “anticipate”, “predict”, “hope”, “intend”, “should”, “try to achieve”, “will estimate”, “long-term” and expressions are used similar, with regard to the Grifols Group, to identify long-term projections and assumptions. These expressions reflect the assumptions, assumptions, expectations and predictions of the control team at the time of writing this report, and are subject to a number of points that mean that actual effects would likely be materially different. The long-term effects of the Grifols organization may also be affected by events related to its own activity, such as shortages of raw materials or fabrics for the manufacture of its products, the appearance on the market of competing products or adjustments in the market. regulatory framework of the markets in which it operates, among others. As of the date of preparation of this report, the Grifols organization has followed the mandatory measures to mitigate the possible impact on such occasions. Grifols, S. A. does not assume any legal responsibility to publicly report, review or update its long-term projections or assumptions to adapt them to occasions or cases after the date of preparation of this report, unless expressly required by applicable legislation. This document does not constitute an offer or invitation to acquire or subscribe for shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of October 23, which approves the consolidated text of the Securities Market Law. Values; Royal Decree-Law 5/2005, of March 11 and/or Royal Decree 1310/2005, of November 4, and any regulations derived from this law. Furthermore, this document does not constitute an offer to acquire, sell or exchange, or a solicitation of an offer to acquire, sell or exchange any securities, or a solicitation of voting or approval in any other jurisdiction. The data included in this document has not been verified or reviewed through the external auditors of the Grifols Group.